Tofacitinib is a rheumatoid arthritis drug which is being developed by Pfizer. The drug, which is in the second of six late-stage clinical trials, has reportedly shown that it reduces signs and symptoms of rheumatoid arthritis by a statistically significant amount when compared to placebo at 6 months. At 3 months, tofacitinib showed that it significantly improved physical function -- and also at 6 months, the drug reduced disease activity.
Tofacitinib was tested in patients with moderate to severe rheumatoid arthritis who had failed traditional treatments. Tofacitinib, previously known as tasocitinib, belongs to a new class of drugs for rheumatoid arthritis called JAK inhibitors, so named because the drug targets the protein JAK (Janus kinase). Tofacitinib is an oral therapy and it's expected to compete well against biologic injectables. Other drugmakers are also developing JAK inhibitors, but Pfizer's tofacitinib is the furthest along in the pipeline.
- Tofacitinib Will Rival Injectable Biologics
- Biologics Explained
- TNF-alpha Blockers - What You Need to Know
- Severe Rheumatoid Arthritis - What You Need to Know
Photo © A.D.A.M.